Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.17 USD
+0.01 (0.32%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $3.16 -0.01 (-0.32%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 401 - 420 ( 439 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q14 Update-Multiple Trials Fated for 2015 Readout
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events from the Week of March 9th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ProHema Passes Second Interim Review in PUMA, Awaiting Final Data in Mid-15, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE-The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec 15
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology/Biopharmaceuticals/BioDefense-Recap of American Society for Hematology Meeting (ASH) 2014 Presentations
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2014 Highlights From Days 1-2-More than CARs and Checkpoints
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 17
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3:14, Data-Rich 2015, Exciting Preclinical Data for ProHema in Peripheral Blood to be Presented at ASH, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov 10
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 13
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent Novartis Investment in Gamida Cell Points to FATE Shares as Undervalued, Reiterate Outperform
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Recent Novartis Investment in Gamida Cell Points to FATE Shares as Undervalued, Reiterate Outperform
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:14, Interim PUMA Review Shows Improved ProHema Formulation is Safe, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Aug 11
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE-The Week Ahead in Life Sciences - Upcoming Events for the Week of July 21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L